دورية أكاديمية
أعرض في EDS

Longitudinal quality of life after sublobar resection and stereotactic body radiation therapy for early-stage non-small cell lung cancer.

التفاصيل البيبلوغرافية
العنوان: Longitudinal quality of life after sublobar resection and stereotactic body radiation therapy for early-stage non-small cell lung cancer.
المؤلفون: Wisnivesky JP; Division of General Internal Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.; Division of Pulmonary, Critical Care and Sleep Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA., Mudd J; Division of Pulmonary, Critical Care and Sleep Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA., Stone K; Division of General Internal Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA., Slatore CG; Division of Pulmonary & Critical Care Medicine, Department of Medicine, and Department of Radiation Medicine, Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, USA.; Center to Improve Veteran Involvement in Care, Veterans Affairs (VA) Portland Health Care System, Portland, Oregon, USA.; Section of Pulmonary & Critical Care Medicine, VA Portland Health Care System, Portland, Oregon, USA., Flores R; Department of Thoracic Surgery, Icahn School of Medicine at Mount Sinai, New York, New York, USA., Swanson S; Department of Thoracic Surgery, Brigham and Women's Hospital, Boston, Massachusetts, USA., Blackstock W Jr; Department of Radiation Oncology, Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, USA., Smith CB; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA., Chidel M; Department of Radiation Oncology, Colorado Permanente Medical Group, Denver, Colorado, USA., Rosenzweig K; Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, New York, USA., Henschke C; Department of Radiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA., Kern JA; Division of Medical Oncology, Department of Medicine, National Jewish Health, Denver, Colorado, USA.
المصدر: Cancer [Cancer] 2024 Mar 21. Date of Electronic Publication: 2024 Mar 21.
Publication Model: Ahead of Print
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Wiley Country of Publication: United States NLM ID: 0374236 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0142 (Electronic) Linking ISSN: 0008543X NLM ISO Abbreviation: Cancer Subsets: MEDLINE
أسماء مطبوعة: Publication: <2005- >: Hoboken, NJ : Wiley
Original Publication: New York [etc.] Published for the American Cancer Society by J. Wiley [etc.]
مستخلص: Background: Many patients with early-stage lung cancer are not candidates for lobectomy because of various factors, with treatment options including sublobar resection or stereotactic body radiation therapy (SBRT). Limited information exists regarding patient-centered outcomes after these treatments.
Methods: Subjects with stage I-IIA non-small cell lung cancer (NSCLC) at high risk for lobectomy who underwent treatment with sublobar resection or SBRT were recruited from five medical centers. Quality of life (QOL) was compared with the Short Form 8 (SF-8) for physical and mental health and Functional Assessment of Cancer Therapy-Lung (FACT-L) surveys at baseline (pretreatment) and 7 days, 30 days, 6 months, and 12 months after treatment. Propensity score methods were used to control for confounders.
Results: Of 337 subjects enrolled before treatment, 63% received SBRT. Among patients undergoing resection, 89% underwent minimally invasive video-assisted thoracic surgery or robot-assisted resection. Adjusted analyses showed that SBRT-treated patients had both higher physical health SF-8 scores (difference in differences [DID], 6.42; p = .0008) and FACT-L scores (DID, 2.47; p = .004) at 7 days posttreatment. Mental health SF-8 scores were not different at 7 days (p = .06). There were no significant differences in QOL at other time points, and all QOL scores returned to baseline by 12 months for both groups.
Conclusions: SBRT is associated with better QOL immediately posttreatment compared with sublobar resection. However, both treatment groups reported similar QOL at later time points, with a return to baseline QOL. These findings suggest that sublobar resection and SBRT have a similar impact on the QOL of patients with early-stage lung cancer deemed ineligible for lobectomy.
(© 2024 American Cancer Society.)
References: Brunelli A, Kim AW, Berger KI, Addrizzo‐Harris DJ. Physiologic evaluation of the patient with lung cancer being considered for resectional surgery: Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians evidence‐based clinical practice guidelines. Chest. 2013;143(suppl 5):e166S‐e190S. doi:10.1378/chest.12‐2395.
Zhang Y, Sun Y, Wang R, Ye T, Zhang Y, Chen H. Meta‐analysis of lobectomy, segmentectomy, and wedge resection for stage I non‐small cell lung cancer. J Surg Oncol. 2015;111(3):334‐340. doi:10.1002/jso.23800.
Timmerman R, Paulus R, Galvin J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA. 2010;303(11):1070‐1076. doi:10.1001/jama.2010.261.
Fakiris AJ, McGarry RC, Yiannoutsos CT, et al. Stereotactic body radiation therapy for early‐stage non‐small‐cell lung carcinoma: four‐year results of a prospective phase II study. Int J Radiat Oncol Biol Phys. 2009;75(3):677‐682. doi:10.1016/j.ijrobp.2008.11.042.
Onishi H, Shirato H, Nagata Y, et al. Stereotactic body radiotherapy (SBRT) for operable stage I non‐small‐cell lung cancer: can SBRT be comparable to surgery? Int J Radiat Oncol Biol Phys. 2011;81(5):1352‐1358. doi:10.1016/j.ijrobp.2009.07.1751.
Chang JY, Senan S, Paul MA, et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non‐small‐cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol. 2015;16(6):630‐637. doi:10.1016/s1470‐2045(15)70168‐3.
Ezer N, Veluswamy RR, Mhango G, Rosenzweig KE, Powell CA, Wisnivesky JP. Outcomes after stereotactic body radiotherapy versus limited resection in older patients with early‐stage lung cancer. J Thorac Oncol. 2015;10(8):1201‐1206. doi:10.1097/jto.0000000000000600.
Port JL, Parashar B, Osakwe N, et al. A propensity‐matched analysis of wedge resection and stereotactic body radiotherapy for early stage lung cancer. Ann Thorac Surg. 2014;98(4):1152‐1159. doi:10.1016/j.athoracsur.2014.04.128.
Nugent SM, Golden SE, Hooker ER, et al. Longitudinal health‐related quality of life among individuals considering treatment for stage I non‐small‐cell lung cancer. Ann Am Thorac Soc. 2020;17(8):988‐997. doi:10.1513/AnnalsATS.202001‐029OC.
Louie AV, van Werkhoven E, Chen H, et al. Patient reported outcomes following stereotactic ablative radiotherapy or surgery for stage IA non‐small‐cell lung cancer: results from the ROSEL multicenter randomized trial. Radiother Oncol. 2015;117(1):44‐48. doi:10.1016/j.radonc.2015.08.011.
Chang JY, Mehran RJ, Feng L, et al. Stereotactic ablative radiotherapy for operable stage I non‐small‐cell lung cancer (revised STARS): long‐term results of a single‐arm, prospective trial with prespecified comparison to surgery. Lancet Oncol. 2021;22(10):1448‐1457. doi:10.1016/s1470‐2045(21)00401‐0.
Yu XJ, Dai WR, Xu Y. Survival outcome after stereotactic body radiation therapy and surgery for early stage non‐small cell lung cancer: a meta‐analysis. J Invest Surg. 2018;31(5):440‐447. doi:10.1080/08941939.2017.1341573.
Zheng X, Schipper M, Kidwell K, et al. Survival outcome after stereotactic body radiation therapy and surgery for stage I non‐small cell lung cancer: a meta‐analysis. Int J Radiat Oncol Biol Phys. 2014;90(3):603‐611. doi:10.1016/j.ijrobp.2014.05.055.
Cao C, Wang D, Chung C, et al. A systematic review and meta‐analysis of stereotactic body radiation therapy versus surgery for patients with non‐small cell lung cancer. J Thorac Cardiovasc Surg. 2019;157(1):362.e8‐373.e8. doi:10.1016/j.jtcvs.2018.08.075.
Ijsseldijk MA, Shoni M, Siegert C, et al. Oncologic outcomes of surgery versus SBRT for non‐small‐cell lung carcinoma: a systematic review and meta‐analysis. Clin Lung Cancer. 2021;22(3):e235‐e292. doi:10.1016/j.cllc.2020.04.017.
Poghosyan H, Sheldon LK, Leveille SG, Cooley ME. Health‐related quality of life after surgical treatment in patients with non‐small cell lung cancer: a systematic review. Lung Cancer. 2013;81(1):11‐26. doi:10.1016/j.lungcan.2013.03.013.
Lagerwaard FJ, Aaronson NK, Gundy CM, Haasbeek CJ, Slotman BJ, Senan S. Patient‐reported quality of life after stereotactic ablative radiotherapy for early‐stage lung cancer. J Thorac Oncol. 2012;7(7):1148‐1154. doi:10.1097/JTO.0b013e318252cfef.
Schwartz RM, Alpert N, Rosenzweig K, Flores R, Taioli E. Changes in quality of life after surgery or radiotherapy in early‐stage lung cancer. J Thorac Dis. 2019;11(1):154‐161. doi:10.21037/jtd.2018.12.30.
Kroenke K, Spitzer RL, Williams JBW, Löwe B. An ultra‐brief screening scale for anxiety and depression: the PHQ–4. Psychosomatics. 2009;50(6):613‐621. doi:10.1016/s0033‐3182(09)70864‐3.
Shah A, Phongsathorn V, Bielawska C, Katona C. Screening for depression among geriatric inpatients with short versions of the Geriatric Depression Scale. Int J Geriatr Psychiatry. 1996;11(10):915‐918. doi:10.1002/(SICI)1099‐1166(199610)11:10<915::AID‐GPS411>3.0.CO;2‐H.
Borson S, Scanlan JM, Chen P, Ganguli M. The Mini‐Cog as a screen for dementia: validation in a population‐based sample. J Am Geriatr Soc. 2003;51(10):1451‐1454. doi:10.1046/j.1532‐5415.2003.51465.x.
Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax. 1999;54(7):581‐586. doi:10.1136/thx.54.7.581.
ECOG Performance Status Scale. ECOG‐ACRIN Cancer Research Group. Accessed June 2021. https://ecog‐acrin.org/resources/ecog‐performance‐status.
Rothrock NE, Amtmann D, Cook KF. Development and validation of an interpretive guide for PROMIS scores. J Patient Rep Outcomes. 2020;4(1):16. doi:10.1186/s41687‐020‐0181‐7.
Amin MB, Edge SB, Greene FL, et al. AJCC Cancer Staging Manual. Vol 1024. Springer; 2017.
Ware J Jr, Kosinski M, Keller SD. A 12‐item short‐form health survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996;34(3):220‐233. doi:10.1097/00005650‐199603000‐00003.
Cella DF, Bonomi AE, Lloyd SR, Tulsky DS, Kaplan E, Bonomi P. Reliability and validity of the Functional Assessment of Cancer Therapy—Lung (FACT‐L) quality of life instrument. Lung Cancer. 1995;12(3):199‐220. doi:10.1016/0169‐5002(95)00450‐f.
Lang L, Zhang L, Zhang P, Li Q, Bian J, Guo Y. Evaluating the reliability and validity of SF‐8 with a large representative sample of urban Chinese. Health Qual Life Outcomes. 2018;16(1):55. doi:10.1186/s12955‐018‐0880‐4.
Swigris JJ, Brown KK, Behr J, et al. The SF‐36 and SGRQ: validity and first look at minimum important differences in IPF. Respir Med. 2010;104(2):296‐304. doi:10.1016/j.rmed.2009.09.006.
Burfeind WR Jr, Tong BC, O’Branski E, et al. Quality of life outcomes are equivalent after lobectomy in the elderly. J Thorac Cardiovasc Surg. 2008;136(3):597‐604. doi:10.1016/j.jtcvs.2008.02.093.
Thompson M, Rosenzweig KE. The evolving toxicity profile of SBRT for lung cancer. Transl Lung Cancer Res. 2019;8(1):48‐57. doi:10.21037/tlcr.2018.10.06.
Chen H, Louie AV, Boldt RG, Rodrigues GB, Palma DA, Senan S. Quality of life after stereotactic ablative radiotherapy for early‐stage lung cancer: a systematic review. Clin Lung Cancer. 2016;17(5):e141‐e149. doi:10.1016/j.cllc.2015.12.009.
Wolff HB, Alberts L, Kastelijn EA, et al. Differences in longitudinal health utility between stereotactic body radiation therapy and surgery in stage I non‐small cell lung cancer. J Thorac Oncol. 2018;13(5):689‐698. doi:10.1016/j.jtho.2018.01.021.
Park HS, Detterbeck FC, Madoff DC, et al. A guide for managing patients with stage I NSCLC: deciding between lobectomy, segmentectomy, wedge, SBRT and ablation—part 4: systematic review of evidence involving SBRT and ablation. J Thorac Dis. 2022;14(6):2412‐2436. doi:10.21037/jtd‐21‐1826.
معلومات مُعتمدة: UL1TR004419 United States TR NCATS NIH HHS; R01CA203193 United States CA NCI NIH HHS
فهرسة مساهمة: Keywords: early‐stage lung cancer; limited resection; non–small cell lung cancer; quality of life; stereotactic body radiation therapy
تواريخ الأحداث: Date Created: 20240321 Latest Revision: 20240321
رمز التحديث: 20240321
DOI: 10.1002/cncr.35286
PMID: 38511395
قاعدة البيانات: MEDLINE
الوصف
تدمد:1097-0142
DOI:10.1002/cncr.35286